Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Non-Current Liabilities: 2017-2023

Historic Other Non-Current Liabilities for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2023 value amounting to $379,000.

  • Denali Therapeutics' Other Non-Current Liabilities changed negligibly% to $379,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $379,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $379,000 for FY2022, which is negligibly% changed negligibly from last year.
  • As of Q3 2023, Denali Therapeutics' Other Non-Current Liabilities stood at $379,000, which was down 0.00% from $379,000 recorded in Q2 2023.
  • In the past 5 years, Denali Therapeutics' Other Non-Current Liabilities registered a high of $701,000 during Q4 2020, and its lowest value of $379,000 during Q4 2019.
  • In the last 3 years, Denali Therapeutics' Other Non-Current Liabilities had a median value of $379,000 in 2023 and averaged $466,818.
  • As far as peak fluctuations go, Denali Therapeutics' Other Non-Current Liabilities spiked by 211.29% in 2019, and later slumped by 45.93% in 2021.
  • Denali Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $379,000 in 2019, then surged by 84.96% to $701,000 in 2020, then plummeted by 45.93% to $379,000 in 2021, then remained steady at $379,000 in 2022, then remained steady at $379,000 in 2023.
  • Its Other Non-Current Liabilities was $379,000 in Q3 2023, compared to $379,000 in Q2 2023 and $379,000 in Q1 2023.